<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172701</url>
  </required_header>
  <id_info>
    <org_study_id>0205-0542</org_study_id>
    <nct_id>NCT04172701</nct_id>
  </id_info>
  <brief_title>A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)</brief_title>
  <official_title>CITRUS Study (Comparing the Incidence Between Tiotropium and ICS/LABA in Real World Use in South Korea)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, Single-country study based on existing data from medical records of COPD
      patients treated with LAMA or fixed dose combination of ICS/LABA
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recorded pneumonia based on Korean Guideline</measure>
    <time_frame>Upto 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of CPT code of chest x-ray(71045-71048) or chest CT(71250,71260,71270,G0297)</measure>
    <time_frame>Upto 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of prescription of antibiotics for pneumonia in Korean Guideline</measure>
    <time_frame>Upto 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency rate of COPD exacerbation</measure>
    <time_frame>Upto 1 year</time_frame>
    <description>Moderate exacerbation: recorded as when COPD patients visited outpatient clinics with an ICD-10 code of COPD and systemic steroid medication and/or antibiotics were prescribed (within the first year after initial prescription of inhalers) Severe exacerbation: when COPD patients visited the emergency room or were admitted to hospital with an ICD-10 code of COPD(due to COPD worsening) and were prescribed systemic steroid medication and/or antibiotics (within the first year after initial prescription of inhalers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to start triple combination therapy (ICS/LABA/LAMA)</measure>
    <time_frame>Upto 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health care utilization costs</measure>
    <time_frame>Upto 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Upto 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of lung cancer (based on ICD-10 code C34.XX)</measure>
    <time_frame>Upto 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9513</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects with Chronic Obstructive Pulmonary Disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting Muscarinic Antagonists (LAMA)</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Chronic Obstructive Pulmonary Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Chronic Obstructive Pulmonary Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with chronic obstrutive pulmonary disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with COPD [based on ICD-10 code(J43.x-44.x except J430), as the primary or
             within the fourth secondary diagnosis and initiated LAMA or ICS/LABA more than twice a
             year from Jan 1, 2005 to Apr 30 2016].

          -  Age &gt;55 years old

        Exclusion Criteria:

          -  Prescription history with any long acting bronchodilator for maintenance therapy (the
             patient should be inhaler naïve)

          -  Prescription history with ipratropium bromide

          -  Prescription history with Leukotriene receptor antagonist(LTRA) or ICS

          -  Patients with lung cancer, IPF, ILD or lung transplantation at the time of COPD
             diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https:// trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

